The Clinical and Forensic Toxicology of Z-drugs
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
The Z-drugs zolpidem, zopiclone, and zaleplon were hailed as the innovative hypnotics of the new millennium, an improvement to traditional benzodiazepines in the management of insomnia. Increasing reports of adverse events including bizarre behavior and falls in the elderly have prompted calls for caution and regulation. Z-drugs have significant hypnotic effects by reducing sleep latency and improving sleep quality, though duration of sleep may not be significantly increased. Z-drugs exert their effects through increased γ-aminobutyric acid (GABA) transmission at the same GABA-type A receptor as benzodiazepines. Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1-7 h). Zopiclone with the longest duration of action has the greatest residual effect, similar to short-acting benzodiazepines. Neuropsychiatric adverse events have been reported with zolpidem including hallucinations, amnesia, and parasomnia. Poisoning with Z-drugs involves predominantly sedation and coma with supportive management being adequate in the majority. Flumazenil has been reported to reverse sedation from all three Z-drugs. Deaths from Z-drugs are rare and more likely to occur with polydrug overdose. Z-drugs can be detected in blood, urine, oral fluid, and postmortem specimens, predominantly with liquid chromatography-mass spectrometry techniques. Zolpidem and zaleplon exhibit significant postmortem redistribution. Zaleplon with its ultra-short half-life has been detected in few clinical or forensic cases possibly due to assay unavailability, low frequency of use, and short window of detection. Though Z-drugs have improved pharmacokinetic profiles, their adverse effects, neuropsychiatric sequelae, and incidence of poisoning and death may prove to be similar to older hypnotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence 3 9 38 suggests that pharmacodynamic factors—such as selectivity for specific GABA A receptor subunits—and pharmacokinetic parameters—such as half-life and absorption rate—play a crucial role in determining the risk of dependence, withdrawal, and adverse effects associated with these agents.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These differences are consistent with the mechanism of action and pharmacological properties of benzodiazepines and z-drugs.”
From Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health (2023) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Z-drugs bind preferentially to GABAA receptors containing α1-subunits, which modulate sedation and amnesia (25, 26).”
From Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health (2023) · cites this paper as [25]
In the citing paper
“Benzodiazepines and z-drugs are positive allosteric modulators of the GABA-A receptor, producing their clinical effects by enhancing the effect of the neurotransmitter GABA at the GABA-A receptor (Cheng, Wallace, Ponteri, & Tuli, 2018; Gunja, 2013).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Gunja, 2013
In the citing paper
“Medications with longer half-lives (such as eszopiclone) are generally associated with lower potential for dependence, whereas those with shorter half-lives (such as zolpidem and zaleplon) are more likely to promote repeated dosing and behavioral reinforcement.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [3]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disposition of Toxic Drugs and Chemicals in Man
Baselt, R. C. (1982) · Medical Entomology and Zoology · Cited by 1,813
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161 · cited 1×
“Some studies quote that up to a third of elderly North Americans are prescribed either a Z-drug or benzodiazepine for sleep disturbance, an alarming statistic given the risks associated with hypnotics in the elderly [3].”
BackgroundDisposition of Toxic Drugs and Chemicals in Man
Christensen, H. (1983) · Forensic Science International · doi:10.1016/0379-0738(83)90025-7 · Cited by 565
Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404 · cited 1×
“Tolerance, dependence, and withdrawal are all reported with Z-drugs, though this appears to be less severe and with lower incidence than for traditional benzodiazepines in the treatment of insomnia [5, 13, 40, 41].”
BackgroundPrinciples of Forensic Toxicology
(2020) · Springer eBooks · doi:10.1007/978-3-030-42917-1 · Cited by 385
Oral fluid testing for drugs of abuse
Bosker, W. M., & Huestis, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.108670 · Cited by 378
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Stewart, R., Besset, A., Bebbington, P., Brugha, T., Lindesay, J., Jenkins, R., Singleton, N., & Meltzer, H. (2006) · Sleep · doi:10.1093/sleep/29.11.1391 · Cited by 274
Cited by
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174730 · Cited by 225
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
“Fatalities were here reported for all Z-drugs, although this typically occurred mostly with zolpidem and zopiclone, both typically ingested in a poly-drug misuse scenario, thus confirming previous reports (Garnier et al., 1994; Casula et al., 2013; Gunja, 2013).”
InfluentialHerbal medicine for insomnia: A systematic review and meta-analysis
Leach, M. J., & Page, A. T. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.12.003 · Cited by 184
In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0294-y · Cited by 177
Self-citation
Metadata
- Authors
- Gunja, N.
- Affiliations
- Children's Hospital at Westmead (AU)
- Corresponding author
- Gunja, Naren
- ORCID
- Gunja, Naren
- Venue
- Journal of Medical Toxicology
- Published
- 2013-02-13
- Volume
- 9
- Issue
- 2
- Pages
- 155-162
- ISSN
- 1556-9039 (ISSN-L)
- 1937-6995
- PMC
- PMC3657020
- OpenAlex
- W1990757549
- Cited by
- 230
- References
- 79
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 15 · 2023: 26 · 2022: 11 · 2021: 24 · 2020: 30 · 2019: 19 · 2018: 16 · 2017: 17 · 2016: 10 · 2015: 9 · 2014: 14 · 2013: 2
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Medical Toxicology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Historical and Scientific Studies
- Keywords
- Z-drugs, zolpidem, zopiclone, zaleplon, hypnotics, insomnia, GABAA receptor, pharmacokinetics, adverse events, postmortem redistribution, drug poisoning, flumazenil, forensic toxicology, drug detection, neuropsychiatric adverse effects
- MeSH terms
- Zolpidem, Acetamides, Coma, Flumazenil, Humans, Hypnotics and Sedatives, Piperazines, Pyridines, Pyrimidines, GABA Modulators, Azabicyclo Compounds, GABA-A Receptor Agonists, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical and Forensic Toxicology of Z-drugs. https://app.cochat.ai/papers/10.1007/s13181-013-0292-0
- The paper
- Gunja, N. (2013). The Clinical and Forensic Toxicology of Z-drugs. Journal of Medical Toxicology. https://doi.org/10.1007/s13181-013-0292-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.